基于手机应用的COVID-19疫苗队列事件监测研究
研究采用前瞻性、非干预性、基于人群的队列设计,通过智能手机应用收集COVID-19疫苗接种后自我报告的不良事件。共纳入732,864名至少接种一剂疫苗的参与者,收集1,436,039剂次接种数据,68%的接种报告至少一种不良事件,88%为 solicited 局部和全身反应原性,0.36%的接种需要医疗护理,结果支持COVID-19疫苗的安全性。
要点
- 68%的接种报告至少一种不良事件,其中88%为 solicited 局部和全身反应。
- 年龄、性别、疫苗产品和剂次是 solicited 不良事件的潜在预测因素。
- 仅0.36%的接种报告需要医疗护理,总体安全性良好。
核心结论
- 研究结果总体支持COVID-19疫苗的安全性。
- 使用原生应用监测自我报告的不良事件是一种创新的药物警戒方法。
研究设计与样本
- 前瞻性、非干预性、基于人群的队列研究(SafeVac2.0),通过智能手机应用在接种第一或第二剂后48小时内允许参与。
- 研究期间为2020年12月26日至2022年9月30日,共739,216人符合主要纳入标准,其中732,864人记录了至少一次接种。
- 收集了1,436,039剂次接种的数据,不良事件收集至第一剂后3周、第二剂后8周、加强剂后7天,并在第一剂后6和12个月询问健康状况。
主要发现
- 68%的接种报告至少一种不良事件,共报告4,007,149个不良事件。
- 88%的不良事件为 solicited 局部和全身反应原性。
- 年龄、性别、疫苗产品和剂次是 solicited 不良事件的潜在预测因素。
- 0.36%的接种报告需要医疗护理。
临床怎么用
- 可利用手机应用主动监测疫苗接种后自我报告的不良事件,补充被动监测。
- 关注年龄、性别、疫苗产品和剂次等潜在预测因素对 solicited 不良事件的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccine pharmacovigilance is critically important to ensure transparent information related to vaccine safety. We conducted a prospective, non-interventional, population-based cohort study, SafeVac2.0, in order to supplement passive surveillance of COVID-19 vaccines by collecting self-reported adverse events (AEs). Participation via smartphone app was allowed within 48 h after the administration of the first or second dose of a COVID-19 vaccine. Adverse events were collected up to 3 weeks after the first vaccination, 8 weeks after the second vaccination, and 7 days after the booster dose. Participants were also asked about their health condition 6 and 12 months after the first dose registered. The study was conducted from December 26, 2020 to September 30, 2022. A total of 739,216 persons met the primary inclusion criteria, of which 732,864 documented at least one vaccination. Data on 1,436,039 vaccinations were collected. At least one AE was reported for 68% of the vaccinations and in total 4,007,149 AEs were reported. 88% of AEs consisted of solicited local and systemic reactogenicity. Age, sex, vaccine product and dose were potential predictors for solicited adverse events. The need for medical care was reported in 0.36% of vaccinations. Overall, the study results provide reassurance of the safety profile of COVID-19 vaccines. The use of a native app to monitor self-reported adverse events represents an innovative pharmacovigilance approach.
引用
- Kopp L, Hofner B, Mentzer D, et al. Mobile-app-based cohort event monitoring study (CEM) of COVID-19 vaccines. Vaccine. 2026. PMID: 42843285. doi:10.1016/j.vaccine.2026.129219
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。